Astellas Pharma logo
Astellas Pharma
ALPMY | OTC
Chart Builder DCF Calculator
$16.95
+$0.11 (+0.62%)
At close: Nov 16, 2026, 3:58 PM ET
$16.95
$0.00 (0.00%)
After-hours: Nov 16, 2026, 3:58 PM ET

Astellas Pharma Company Profile

Company profile explained

Company Profile

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide. The company's diverse pipeline and marketed portfolio address critical unmet medical needs across various therapeutic areas. In oncology, Astellas offers XTANDI, an androgen receptor signaling inhibitor used in prostate cancer; XOSPATA, a FLT3 inhibitor designed for adults with relapsed or refractory acute myeloid leukemia characterized by a FLT3 mutation; and PADCEV, a treatment option for patients with locally advanced or metastatic urothelial cancer. For urological conditions, key offerings include Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist managing urgency, urinary frequency, and urge urinary incontinence, alongside Vesicare for overactive bladder and mirabegron specifically for pediatric neurogenic detrusor overactivity. Other urology-related products include Eligard for prostate cancer and Harnal/Omnic for benign prostatic hyperplasia. Beyond oncology and urology, the company provides Evrenzo, an oral medication for anemia linked to chronic kidney disease, and the immunosuppressant family Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ rejection in transplant recipients. Funguard/MYCAMINE serves as an antifungal agent. Astellas actively engages in numerous strategic collaborations to expand its innovation pipeline. These include clinical trial partnerships with Merck & Co., Inc. and CytomX Therapeutics, Inc., as well as an innovative agreement with BANDAI NAMCO Entertainment Inc. to develop a smartphone-based exercise support application. Further alliances encompass a strategic research partnership with Harvard University focused on therapeutics and technologies, a research collaboration with Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies using its Antibody Warhead Enabling platform, and an agreement with Zenith Epigenetics Ltd. for the evaluation of ZEN-3694. The company also maintains a collaboration with Cytokinetics, Incorporated, and has forged a strategic partnership and license agreement with Minovia Therapeutics Ltd. to develop cell therapy programs addressing diseases stemming from mitochondrial dysfunction. Founded in 1923, Astellas Pharma Inc. maintains its corporate headquarters in Tokyo, Japan.

Key Executives

Name Position
Naoki Okamura President, CEO & Representative Director
Atsushi Kitamura Chief Financial Officer
Katsuyoshi Sugita Executive Vice President, Chief People Officer & Representative Director
Jun Kono Senior Executive Officer & Head of Japan Commercial
Leticia Delgado-Herrera Vice President and Rx+ M&D Head
Nahrin Marino General Counsel and Chief Ethics & Compliance Officer
Nobuaki Tanaka President of Japan Commercial & Senior Corporate Executive
Nobue Yasuda General Manager of Finance & Accounting Department
Nobuko Kato Chief Communications & Investor Relations Officer
Nori Kuwahara Senior Vice President of Planning & Administration
Tatjana Dragovic General Counsel, Chief Ethics & Compliance Officer
Yoshitsugu Shitaka Chief Scientific Officer & Senior Managing Executive Officer
Astellas Pharma
Astellas Pharma logo
Country Japan
IPO Date Dec 29, 2009
Industry Drug Manufacturers - General
Sector Healthcare
Employees 14,099
CEO Naoki Okamura

Contact Details

2-5-1, Nihonbashi-Honcho Tokyo, TY 103-8411 Japan

Stock Details

Ticker Symbol ALPMY
Exchange OTC
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001376684
CUSIP Number 04623U102
ISIN Number US04623U1025
SIC Code

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.